Comparative Pharmacology
Head-to-head clinical analysis: BROMPHENIRAMINE MALEATE versus CETIRIZINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMPHENIRAMINE MALEATE versus CETIRIZINE HYDROCHLORIDE.
BROMPHENIRAMINE MALEATE vs CETIRIZINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of histamine at H1 receptor sites, suppressing histamine-induced vasodilation, increased capillary permeability, and bronchoconstriction.
Selective histamine H1-receptor antagonist; inhibits histamine-mediated allergic and inflammatory responses.
4 mg orally every 4-6 hours, not to exceed 24 mg/day. Alternatively, extended-release: 12 mg every 12 hours.
5-10 mg orally once daily; maximum 10 mg per day.
None Documented
None Documented
Terminal half-life 22-25 hours; prolonged in hepatic impairment or elderly (up to 40 hours).
Terminal elimination half-life is approximately 8-11 hours in healthy adults; prolonged in renal impairment (up to 20-30 hours in moderate to severe impairment).
Renal (85-90% as metabolites, 5-10% unchanged); biliary/fecal <5%.
Primarily renal (approximately 70% as unchanged drug via glomerular filtration and tubular secretion); minor biliary/fecal elimination (<10%).
Category C
Category A/B
Antihistamine
Antihistamine